Tumor Necrosis Factor and Coagulopathy in Patients with Prostate Cancer

Abstract

This study was undertaken to evaluate the relationship between serum tumor necrosis factor (TNF) and coagulopathy in patients with prostate cancer. TNF levels in 104 sera obtained from 101 prostate cancer patients were determined using an enzyme immunoassay. Serum levels of fibrin/fibrinogen degradation product E fragment (FDP) and plasma levels of fibrin degradation product d-dimer in patients with elevated serum TNF levels were 1221.95 ± 375.94 ng/ml and 27.34 ± 9.81 µg/ml, which were significantly higher than those (FDP, 94.35 ± 13.17 ng/ml; d-dimer, 1.03 ± 0.20 µg/ml) in patients with undetectable serum TNF levels (P < 0.01). In addition, patients with elevated serum TNF levels showed significant increases in plasma levels of thrombin-antithrombin-III complex and plasmin-α2-antiplasmin inhibitor complex and a significantly higher incidence of positive plasma soluble fibrin monomer complex than did those with undetectable serum TNF levels. The percentage of prothrombin time was significantly decreased in the group with elevated serum levels of TNF. Serum levels of TNF were significantly elevated in patients with serum FDP levels of ≥200 ng/ml than in those with serum FDP levels of <200 ng/ml (3.91 ± 0.45 versus 2.17 ± 0.08 units/ml) and in patients with plasma d-dimer levels of ≥2 µg/ml than in those with plasma d-dimer levels of <2 µg/ml (3.82 ± 0.48 versus 2.10 ± 0.06 units/ml). These results suggest that TNF may be one of the pathogenetic factors that could explain the occurrence of coagulopathy in patients with prostate cancer.